ReviewJournal of cancer research and clinical oncology2020
Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma.
Review in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 182 citations in OpenAlex.
- Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review.Journal of molecular medicine (Berlin, Germany) · 2024Pooled it
- Comparison of the Effects of Sorafenib and Stem Cell Secretome on HepG2 Cancer Cells with Respect to the Ras/Raf/MEK/ERK Pathway.Journal of clinical medicine · 2026Article
- Contrast-enhanced ultrasound and clinical features for preoperative prediction of GPC-3 expression in hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Imaging of pancreatic hepatoid adenocarcinoma: a scoping review.Quantitative imaging in medicine and surgery · 2026Review
- AFP Stimulates Glucose Metabolic Reprogramming Contributing to Hepatocellular Carcinoma Resist Sorafenib Through Activating PI3K/AKT Signalling Pathway.Journal of cellular and molecular medicine · 2026Article
- Assessment of the diagnostic performance and influencing factors of AFP and PIVKA-II in hepatocellular carcinoma.Discover oncology · 2026Article
- Alpha-Fetoprotein Stimulates Cleavage of Membranal MICA/B on Liver Cancer Cell Lead to Escape Immune Surveillance of Natural Killer Cells.Journal of cellular and molecular medicine · 2026Article
- AFP confers the resistance of lenvatinib in hepatocellular carcinoma by activating PI3K/AKT/LDHA signaling axis.Discover oncology · 2026Article
- Review
- Predictive value of an AI model integrating MRI radiomics and clinical features for early recurrence of hepatocellular carcinoma prior to radiofrequency ablation.Frontiers in radiology · 2026Article
- Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case-control study.Molecular oncology · 2025Article
- Isolation and characterisation of AFPStem cell research & therapy · 2025Article
- Article
- Review
- Article
- Enhancing Recurrence-Free Survival Prediction in Hepatocellular Carcinoma: A Time-Updated Model Incorporating Tumor Burden and AFP Dynamics.Annals of surgical oncology · 2025Article
- Nuclear factor IA-mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression.Molecular and clinical oncology · 2025Article
- Expression and prognostic significance of MLH1 and GPRC5C in resectable hepatocellular carcinoma.BMC cancer · 2025Article
- Unusual phenomenon in advanced hepatocellular carcinoma: declining alpha-fetoprotein levels despite disease progression.Discover oncology · 2025Article
- Exploring the Multifunctional Role of Alpha-Fetoprotein in Cancer Progression: Implications for Targeted Therapy in Hepatocellular Carcinoma and Beyond.International journal of molecular sciences · 2025Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. Alpha-fetoprotein (AFP) is considered as a diagnostic and prognostic tumorous marker for HCC, and up to 70% of HCC patients showed elevated serum levels of AFP. In the past two decades, evidences have shown that AFP not only is a tumorous biomarker for diagnosing HCC, but also plays a very complicated role in regulating proliferation, apoptosis, and autophagy and inhibiting the immune response of cells. Because AFP is significantly elevated during hepatocarcinogenesis, the role of AFP in the development of HCC is a scientific problem worthy of further exploration. In this review, we reviewed the effects of AFP on hepatocyte malignant transformation and the underlying mechanisms involved in the progression of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.